Immutep Ltd has released a press release.
Prima initiates Phase I melanoma study in Australia
Filed with ASX ·
6ix hasn’t read this filing yet.
Later from Immutep
- US patent granted for IMP731 antibody
- First patient dosed in AIPAC
- Proposed Acquisition of Immutep
- Appendix 4C - quarterly March 2016
- Japanese Patent Grants For IMP321 In Cancer
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep